TransMedics Group (TMDX) reported Q1 earnings late Thursday of $0.70 per diluted share, up from $0.35 a year earlier.
Analysts polled by FactSet expected $0.26.
Revenue for the quarter ended March 31 was $143.5 million, compared with $96.9 million a year earlier.
Analysts surveyed by FactSet expected $123.7 million.
TransMedics raised its 2025 revenue guidance to a range of $565 million to $585 million from $530 million to $552 million. Analysts surveyed by FactSet expect $559.4 million.
Shares of the company rose 14.5% in after-hours activity Thursday.